Corneal Versus Conjunctival Delivery Using a Delivery Device
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (Industry)
Overall Status
Withdrawn
CT.gov ID
NCT00143429
Collaborator
(none)
0
Study Details
Study Description
Brief Summary
Compare the antihypertensive efficacy of three methods for installing Xalatan
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Study Type:
Interventional
Actual Enrollment
:
0 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single
Primary Purpose:
Treatment
Official Title:
Effect Of Corneal Versus Conjunctival Delivery On The Corneal Safety, Tolerability, and Antihypertensive Efficacy Of The Xalatan Ophthalmic Delivery Device
Outcome Measures
Primary Outcome Measures
- IOP level in the study eye []
Secondary Outcome Measures
- Change in ocular safety assessments. Ocular and systemic adverse events throughout the study period []
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Diagnosis of primary open angle glaucoma or ocular hypertension in 1 or both eyes
Exclusion Criteria:
- History of closed/barely open anterior chamber angle or a history of angle closure
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
ClinicalTrials.gov Identifier:
NCT00143429
Other Study ID Numbers:
- A6111127
First Posted:
Sep 2, 2005
Last Update Posted:
Feb 2, 2021
Last Verified:
Mar 1, 2015
Keywords provided by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Additional relevant MeSH terms: